FULGENT GENETICS, INC. (FLGT) Quick Ratio
- Quick ratio · latest quarter: Value 4.49×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 4.49× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $321.97M ÷ $71.76M ≈ 4.49× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 321.97M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 71.76M USD | Liabilities, Current |
| Cash and equivalents | 26.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 230.73M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 64.94M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 793.00K USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $321.97M | $71.76M | $26.30M | $230.73M | $64.94M | $793.00K | 4.49× |
| 2026-03-31 | $345.58M | $90.13M | $23.40M | $252.90M | $69.28M | $770.00K | 3.83× |
| 2025-12-31 | $420.84M | $84.97M | $50.19M | $285.88M | $84.76M | (m) | 4.95× |
| 2025-09-30 | (m) | $72.43M | $117.64M | (m) | $71.19M | (m) | (m) |
| 2025-06-30 | (m) | $71.33M | $87.88M | (m) | $77.19M | (m) | (m) |
| 2025-03-31 | (m) | $65.92M | $67.28M | (m) | $71.48M | (m) | (m) |
| 2024-12-31 | (m) | $72.90M | $55.14M | (m) | $69.02M | (m) | (m) |
| 2024-09-30 | (m) | $73.99M | $58.04M | (m) | $57.31M | (m) | (m) |
| 2024-06-30 | (m) | $75.75M | $65.11M | (m) | $56.57M | (m) | (m) |
| 2024-03-31 | (m) | $75.95M | $54.68M | (m) | $52.06M | (m) | (m) |
| 2023-12-31 | (m) | $73.02M | $97.47M | (m) | $51.13M | (m) | (m) |
| 2023-09-30 | (m) | $61.42M | $84.08M | (m) | $49.28M | (m) | (m) |
| 2023-06-30 | (m) | $64.82M | $58.35M | (m) | $34.81M | (m) | (m) |
| 2023-03-31 | (m) | $81.94M | $66.17M | (m) | $43.55M | (m) | (m) |
| 2022-12-31 | (m) | $88.11M | $79.51M | (m) | $52.75M | (m) | (m) |
| 2022-09-30 | (m) | $102.52M | $168.77M | (m) | $104.16M | (m) | (m) |
| 2022-06-30 | (m) | $127.53M | $138.78M | (m) | $133.30M | (m) | (m) |
| 2022-03-31 | (m) | $141.71M | $353.07M | (m) | $160.26M | (m) | (m) |
| 2021-12-31 | (m) | $105.31M | $164.89M | (m) | $138.91M | (m) | (m) |
| 2021-09-30 | (m) | $147.16M | $214.88M | (m) | $120.82M | (m) | (m) |
| 2021-06-30 | (m) | $121.52M | $100.46M | (m) | $148.58M | (m) | (m) |
| 2021-03-31 | (m) | $196.53M | $151.46M | (m) | $216.51M | (m) | (m) |
| 2020-12-31 | $483.22M | $130.12M | $87.43M | $211.94M | $183.86M | (m) | 3.71× |
| 2020-09-30 | $165.62M | $57.74M | $53.03M | $21.90M | $90.68M | (m) | 2.87× |
| 2020-06-30 | $34.82M | $6.51M | $2.43M | $18.53M | $13.86M | (m) | 5.35× |
| 2020-03-31 | $33.70M | $5.81M | $9.30M | $18.03M | $6.37M | (m) | 5.80× |
| 2019-12-31 | $34.82M | $3.72M | $11.96M | $16.30M | $6.55M | (m) | 9.35× |
| 2019-09-30 | $37.41M | $4.25M | $20.52M | $11.60M | $5.29M | (m) | 8.80× |
| 2019-06-30 | $32.53M | $2.91M | $9.16M | $17.82M | $5.54M | (m) | 11.18× |
| 2019-03-31 | $33.99M | $3.20M | $5.29M | $24.14M | $4.56M | (m) | 10.61× |
| 2018-12-31 | $36.98M | $2.74M | $6.74M | $24.30M | $5.95M | (m) | 13.51× |
| 2018-09-30 | $38.68M | $2.25M | $8.49M | $24.11M | $6.08M | (m) | 17.15× |
| 2018-06-30 | $35.66M | $2.98M | $3.65M | $26.95M | $5.05M | (m) | 11.97× |
| 2018-03-31 | $33.45M | $2.41M | $5.27M | $23.21M | $4.97M | (m) | 13.89× |
| 2017-12-31 | $30.49M | $3.00M | $6.49M | $19.99M | $4.00M | (m) | 10.16× |
| 2017-09-30 | $29.64M | $3.15M | $9.48M | $16.57M | $3.59M | (m) | 9.41× |
| 2017-06-30 | $33.06M | $2.83M | $11.47M | $17.40M | $4.19M | (m) | 11.69× |
| 2017-03-31 | $31.97M | $3.28M | $6.73M | $20.63M | $4.60M | (m) | 9.74× |
| 2016-12-31 | $25.23M | $3.32M | $7.90M | $12.97M | $4.36M | (m) | 7.61× |
| 2016-09-30 | (m) | $5.01M | (m) | (m) | $4.41M | (m) | (m) |
| 2015-12-31 | (m) | $686.00K | (m) | (m) | $2.12M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |